Amphastar Pharmaceuticals (NASDAQ:AMPH) Downgraded by Zacks Research to “Strong Sell”

Posted by Brian Himes on Jun 24th, 2026

Amphastar Pharmaceuticals (NASDAQ:AMPH – Get Free Report) was downgraded by equities researchers at Zacks Research from a “hold” rating to a “strong sell” rating in a research report issued to clients and investors on Monday,Zacks.com reports.

A number of other research analysts have also weighed in on AMPH. Weiss Ratings lowered shares of Amphastar Pharmaceuticals from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Friday, April 10th. Piper Sandler reissued a “neutral” rating and set a $21.00 price objective (down from $25.00) on shares of Amphastar Pharmaceuticals in a research report on Monday, May 11th. Wells Fargo & Company restated an “equal weight” rating and set a $19.00 price objective (down from $30.00) on shares of Amphastar Pharmaceuticals in a report on Thursday, May 14th. Needham & Company LLC reaffirmed a “hold” rating on shares of Amphastar Pharmaceuticals in a research report on Friday, May 8th. Finally, Jefferies Financial Group reaffirmed a “hold” rating and issued a $22.00 target price (down from $30.00) on shares of Amphastar Pharmaceuticals in a research note on Tuesday, April 21st. Six analysts have rated the stock with a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Reduce” and a consensus target price of $24.00.

View Our Latest Research Report on Amphastar Pharmaceuticals

Amphastar Pharmaceuticals Trading Up 6.5%

NASDAQ:AMPH opened at $19.53 on Monday. The company has a debt-to-equity ratio of 0.79, a current ratio of 3.85 and a quick ratio of 2.82. The business’s 50-day simple moving average is $19.90 and its 200-day simple moving average is $22.96. Amphastar Pharmaceuticals has a fifty-two week low of $16.65 and a fifty-two week high of $31.26. The stock has a market capitalization of $861.08 million, a PE ratio of 11.77, a price-to-earnings-growth ratio of 3.60 and a beta of 0.91.

Amphastar Pharmaceuticals (NASDAQ:AMPH – Get Free Report) last posted its earnings results on Thursday, May 7th. The company reported $0.42 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.70 by ($0.28). Amphastar Pharmaceuticals had a return on equity of 15.12% and a net margin of 11.00%.The business had revenue of $171.17 million for the quarter, compared to the consensus estimate of $173.46 million. Sell-side analysts expect that Amphastar Pharmaceuticals will post 2.41 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Amphastar Pharmaceuticals

Large investors have recently modified their holdings of the business. FNY Investment Advisers LLC acquired a new stake in shares of Amphastar Pharmaceuticals in the third quarter valued at about $26,000. Quarry LP acquired a new position in Amphastar Pharmaceuticals during the third quarter valued at approximately $32,000. Farther Finance Advisors LLC boosted its position in Amphastar Pharmaceuticals by 46.3% during the fourth quarter. Farther Finance Advisors LLC now owns 1,381 shares of the company’s stock valued at $37,000 after purchasing an additional 437 shares during the last quarter. GAMMA Investing LLC grew its stake in Amphastar Pharmaceuticals by 37.8% in the fourth quarter. GAMMA Investing LLC now owns 1,685 shares of the company’s stock valued at $45,000 after purchasing an additional 462 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. grew its stake in Amphastar Pharmaceuticals by 24.2% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,233 shares of the company’s stock valued at $60,000 after purchasing an additional 435 shares in the last quarter. 65.09% of the stock is currently owned by institutional investors and hedge funds.

About Amphastar Pharmaceuticals

(Get Free Report)

Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company headquartered in Rancho Cucamonga, California. Founded in 2004, Amphastar focuses on the development, manufacturing and commercialization of injectable and inhalation products. The company’s manufacturing facilities in California produce both generic and proprietary formulations designed to address urgent and chronic medical conditions.

Amphastar’s portfolio includes a range of injectable generics such as epinephrine, naloxone and lidocaine, serving hospital, emergency medical and retail pharmacy channels.